Skip to main content
Erschienen in: Der Diabetologe 5/2015

01.07.2015 | Leitthema

Arterielle Hypertonie und Herzinsuffizienz

verfasst von: A. Savvaidis, N. Marx, Dr. K. Schütt

Erschienen in: Die Diabetologie | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die Herzinsuffizienz stellt mit einer hohen Prävalenz und assoziierter Morbidität und Letalität ein globales Gesundheitsproblem dar. Arterielle Hypertonie und Diabetes mellitus sind wichtige Risikofaktoren. Beide können über eine Aktivierung des Renin-Angiotensin-Aldosteron-Systems und das sympathische Nervensystem zur Entwicklung der Herzinsuffizienz betragen. Bei Patienten mit Diabetes mellitus spielen zudem Veränderungen des kardialen Metabolismus, vermehrter oxidativer Stress und eine reduzierte Kalziumsensitivität eine zentrale Rolle.

Methode

Die vorliegende Arbeit gibt eine Übersicht zu den pathophysiologischen Veränderungen und therapeutischen Optionen der arteriellen Hypertonie bei Herzinsuffizienz mit Fokus auf Patienten mit Diabetes mellitus.

Ergebnisse

Gemäß den Leitlinien der ESC/EASD wird derzeit für Patienten mit arterieller Hypertonie und Diabetes mellitus ein Zielblutdruck von 140/80–85 mmHg empfohlen. Hierbei sollten Lebensstilmodifikationen mit Fokus auf Gewichtsverlust und Reduktion der Kochsalzzufuhr angestrebt werden. Alle gut tolerierten Medikamente können verwendet werden, jedoch sind bestehende Begleiterkrankungen zu berücksichtigen.
Literatur
1.
Zurück zum Zitat Drummond GA, Squire IB (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13CrossRef Drummond GA, Squire IB (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353:9–13CrossRef
2.
Zurück zum Zitat o A (1987) The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435CrossRef o A (1987) The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435CrossRef
3.
Zurück zum Zitat Davis BR, Cutler JA, Gordon DJ (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997CrossRef Davis BR, Cutler JA, Gordon DJ (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981–2997CrossRef
4.
Zurück zum Zitat Berenji K, Drazner MH, Rothermel BA et al (2005) Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289:H8–H16PubMedCrossRef Berenji K, Drazner MH, Rothermel BA et al (2005) Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol 289:H8–H16PubMedCrossRef
5.
6.
Zurück zum Zitat Brilla CG, Matsubara L, Weber KT (1996) Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 28:269–275PubMedCrossRef Brilla CG, Matsubara L, Weber KT (1996) Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension 28:269–275PubMedCrossRef
7.
Zurück zum Zitat Choi KM, Zhong Y, Hoit BD et al (2002) Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 283:H1398–H1408PubMedCrossRef Choi KM, Zhong Y, Hoit BD et al (2002) Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 283:H1398–H1408PubMedCrossRef
8.
Zurück zum Zitat Cohn JN, Levine TB, Olivari MT et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823PubMedCrossRef Cohn JN, Levine TB, Olivari MT et al (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311:819–823PubMedCrossRef
9.
Zurück zum Zitat Cohn JN, Pfeffer MA, Rouleau J et al (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659–667PubMedCrossRef Cohn JN, Pfeffer MA, Rouleau J et al (2003) Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5:659–667PubMedCrossRef
10.
Zurück zum Zitat Cushman WC, Evans GW, Byington P et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585PubMedCrossRef Cushman WC, Evans GW, Byington P et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585PubMedCrossRef
11.
Zurück zum Zitat Drazner MH, Rame JE, Marino EK et al (2004) Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43:2207–2215PubMedCrossRef Drazner MH, Rame JE, Marino EK et al (2004) Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43:2207–2215PubMedCrossRef
12.
Zurück zum Zitat Essick EE, Sam F (2011) Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens 2011:346985PubMedCentralPubMedCrossRef Essick EE, Sam F (2011) Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Int J Hypertens 2011:346985PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Frustaci A, Kajstura J, Chimenti C et al (2000) Myocardial cell death in human diabetes. Circ Res 87:1123–1132PubMedCrossRef Frustaci A, Kajstura J, Chimenti C et al (2000) Myocardial cell death in human diabetes. Circ Res 87:1123–1132PubMedCrossRef
14.
Zurück zum Zitat Hess K, Marx N, Lehrke M (2012) Cardiovascular disease and diabetes: the vulnerable patient. Eur Heart J Suppl 14:B4–B13CrossRef Hess K, Marx N, Lehrke M (2012) Cardiovascular disease and diabetes: the vulnerable patient. Eur Heart J Suppl 14:B4–B13CrossRef
15.
Zurück zum Zitat Hjalmarson A, Goldstein S, Fagerberg B et al (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295–1302PubMedCrossRef Hjalmarson A, Goldstein S, Fagerberg B et al (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 283:1295–1302PubMedCrossRef
16.
Zurück zum Zitat Jweied EE, Mckinney RD, Walker LA et al (2005) Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol 289:H2478–H2483PubMedCrossRef Jweied EE, Mckinney RD, Walker LA et al (2005) Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol 289:H2478–H2483PubMedCrossRef
17.
Zurück zum Zitat Klingbeil AU, Schneider M, Martus P et al (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41–46PubMedCrossRef Klingbeil AU, Schneider M, Martus P et al (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41–46PubMedCrossRef
18.
Zurück zum Zitat Mann JF, Schmieder RE, Mcqueen M et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553PubMedCrossRef Mann JF, Schmieder RE, Mcqueen M et al (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553PubMedCrossRef
19.
Zurück zum Zitat Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884–893PubMedCrossRef Messerli FH, Mancia G, Conti CR et al (2006) Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 144:884–893PubMedCrossRef
20.
Zurück zum Zitat Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194–2199PubMedCrossRef Packer M, Fowler MB, Roecker EB et al (2002) Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194–2199PubMedCrossRef
21.
Zurück zum Zitat Packer M, O’connor CM, Ghali JK et al (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335:1107–1114PubMedCrossRef Packer M, O’connor CM, Ghali JK et al (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335:1107–1114PubMedCrossRef
22.
Zurück zum Zitat Parving HH, Brenner BM, Mcmurray JJ et al (2012) Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 13:387–393PubMedCrossRef Parving HH, Brenner BM, Mcmurray JJ et al (2012) Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 13:387–393PubMedCrossRef
23.
Zurück zum Zitat Patel A, Macmahon S, Chalmers J et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840PubMedCrossRef Patel A, Macmahon S, Chalmers J et al (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840PubMedCrossRef
24.
Zurück zum Zitat Poole-Wilson PA, Swedberg K, Cleland J et al (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13PubMedCrossRef Poole-Wilson PA, Swedberg K, Cleland J et al (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7–13PubMedCrossRef
26.
Zurück zum Zitat Reboldi G, Gentile G, Angeli F et al (2009) Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther 7:1349–1361PubMedCrossRef Reboldi G, Gentile G, Angeli F et al (2009) Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther 7:1349–1361PubMedCrossRef
27.
Zurück zum Zitat Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951PubMedCrossRef Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951PubMedCrossRef
28.
Zurück zum Zitat Tomanek RJ, Wessel TJ, Harrison DG (1991) Capillary growth and geometry during long-term hypertension and myocardial hypertrophy in dogs. Am J Physiol 261:H1011–H1018PubMed Tomanek RJ, Wessel TJ, Harrison DG (1991) Capillary growth and geometry during long-term hypertension and myocardial hypertrophy in dogs. Am J Physiol 261:H1011–H1018PubMed
29.
Zurück zum Zitat Vermes E, Tardif JC, Bourassa MG et al (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926–2931PubMedCrossRef Vermes E, Tardif JC, Bourassa MG et al (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107:2926–2931PubMedCrossRef
30.
Zurück zum Zitat Weber MA, Bakris GL, Jamerson K et al (2010) Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 56:77–85PubMedCrossRef Weber MA, Bakris GL, Jamerson K et al (2010) Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 56:77–85PubMedCrossRef
Metadaten
Titel
Arterielle Hypertonie und Herzinsuffizienz
verfasst von
A. Savvaidis
N. Marx
Dr. K. Schütt
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Diabetologie / Ausgabe 5/2015
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-015-1359-0

Weitere Artikel der Ausgabe 5/2015

Der Diabetologe 5/2015 Zur Ausgabe

Einführung zum Thema

Hypertonie und Diabetes

Magazin

Magazin

CME Zertifizierte Fortbildung

Aktuelle Aspekte im Herzsport

Mitteilungen der DDS

Mitteilungen DDS

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.